BioAtla: Funding, Investors & Team (Oct 2026)
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
BioAtla has raised $81.7M across 2 funding rounds on record, the most recent an undisclosed round of $9.2M announced in Dec 2024.
That round is in line with the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioAtla Company Profile and Key Stats
Latest funding round on record: Dec 2024.
BioAtla Funding Rounds
BioAtla raised $72.5M in an undisclosed round announced in Jul 2020.
4.4 years later, an undisclosed round of $9.2M was announced in Dec 2024.
BioAtla Founders and Leadership Team
Contact details for the BioAtla team: 1 of 2 have an email address on file.
Start 14-day free trial →BioAtla Funding Compared to Other Biotechnology Startups
BioAtla's latest round of $9.2M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioAtla in Biotechnology and San Diego
Companies Similar to BioAtla
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BioAtla Funding FAQs
What does BioAtla do?
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
How much funding has BioAtla raised?
BioAtla has raised $81.7M across 2 rounds on record. The most recent is an undisclosed round of $9.2M announced in Dec 2024.
When did BioAtla last raise funding?
BioAtla's most recent funding round on record is an undisclosed round of $9.2M, announced in Dec 2024.
Who founded BioAtla?
FundedIQ lists Lauri Koorits (Founder) at BioAtla.
Who is the CEO of BioAtla?
Jay Short is listed as CEO at BioAtla.
Where is BioAtla headquartered?
BioAtla is based in San Diego, California, United States.
How many employees does BioAtla have?
BioAtla is in the 51-100 employee band.
How does BioAtla's funding compare to other Biotechnology startups?
BioAtla's latest round of $9.2M is in line with the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioAtla Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioAtla is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.